CAMP CAMP4 THERAPEUTICS CORPORATION
$3.65▲ +13.71%
Healthcare
Other
Volume 259.8K
Avg Volume (10D) 121.1K
Key Metrics & Fundamentals
Market Cap
$229.05M
P/E Ratio
–
Div Yield
0.00%
52W Range
2.90 - 7.75
% vs 50 MA
-7.40%
% vs 200 MA
-14.17%
RSI-14
50.9
MACD Histogram
+0.0200
Beta (1Y vs SPY)
1.87
Free Cash Flow
-$12.82M
Gross Rev
$1.78M
Gross Profit
$1.78M
EBITDA
$8.07M
COGS
–
Operating Exp
$15.16M
Operating Income
-$13.38M
EBIT
-$13.38M
Pretax Income
-$33.53M
Net Income
-$33.53M
EPS (Diluted)
-0.58
Price & Volume History
Loading chart…
Recent News
CAMP4 Therapeutics Receives Clinical Trial Application Approval for Phase 1/2 Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder in the European Union
GlobeNewswire · Oct 27, 2026 8:00 AM ET
Raymond James Initiates Coverage on CAMP4 Therapeutics With Strong Buy Rating, $10 PT
MT Newswires · Oct 23, 2026 7:26 AM ET
CAMP4 Conference: Korro, Tevard Spotlight RNA Fixes for Genetic Disease
MarketBeat · Oct 20, 2026 11:04 AM ET
Needham & Co Initiates Coverage on CAMP4 Therapeutics With Buy Rating, $8 Price Target
MT Newswires · Oct 15, 2026 7:41 AM ET
CAMP4 to Participate in Chardan’s 10th Annual Healthcare Conference
GlobeNewswire · Oct 14, 2026 8:00 AM ET
Oppenheimer Initiates Coverage on CAMP4 Therapeutics With Outperform Rating, $15 Price Target
MT Newswires · Oct 5, 2026 7:18 AM ET
Chardan Trims Price Target on CAMP4 Therapeutics to $6 From $6.50, Keeps Buy Rating
MT Newswires · Sep 29, 2026 6:53 AM ET
CAMP4 Targets Q4 ASCEND Trial Start for SYNGAP1 Therapy CMP-002
MarketBeat · Sep 28, 2026 3:02 PM ET
CAMP4 Therapeutics Gets Clearance to Conduct Phase 1/2 Study for SYNGAP1-Related Disorder Treatment in UK
MT Newswires · Sep 10, 2026 8:06 AM ET
CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder
GlobeNewswire · Sep 10, 2026 7:33 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See CAMP's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.